1. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011; 29: 415-445. doi: 10.1146/annurevimmunol-031210-101322
2. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016; 12(1): 15-28. doi: 10.1038/nrendo.2015.189
3. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115(5): 1111-1119. doi: 10.1172/JCI200525102DS1
4. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011; 121(6): 2111-2117. doi: 10.1172/JCI57132
5. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL1β. Mol Cell. 2002; 10: 417-426. doi: 10.1016/S1097-2765(02)00599-3
6. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011; 12: 408-415. doi: 10.1038/ni.2022
7. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011; 17: 179-188. doi: 10.1038/nm.2279
8. Stienstra R, Joosten LAB, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010; 12: 593-605. doi: 10.1016/j.cmet.2010.11.011
9. Goossens GH, Blaak EE, Theunissen R, et al. Expression of NLRP3 inflammasome and T-cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol. 2012; 50: 142-149. doi: 10.1016/j.molimm.2012.01.005
10. Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013; 62: 194-204. doi: 10.2337/db12-0420
11. Collino M, Benetti E, Rogazzo M, et al. Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol. 2013; 85(2): 257-264. doi: 10.1016/j. bcp.2012.10.014
12. Chiazza F, Couturier-Maillard A, Benetti E, et al. Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice. Mol Med. 2015; 21: 1025-1037. doi: 10.2119/molmed.2015.00104
13. Mastrocola R, Collino M, Penna C, et al. Maladaptive modulations of NLRP3 inflammasome and cardioprotective pathways are involved in diet-induced exacerbation of myocardial ischemia/reperfusion injury in mice. Oxid Med Cell Longev. 2016; 2016: 3480637. doi: 10.1155/2016/3480637
14. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011; 54: 133-144. doi: 10.1002/hep.24341
15. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482: 179-185. doi: 10.1038/nature10809
16. Csak T, Pillai A, Ganz M, et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int. 2014; 34: 1402-1413. doi: 10.1111/liv.12537
17. Baldwin AG, Brough D, Freeman S. Inhibiting the inflammasome: A chemical perspective. J Med Chem. 2016; 59(5): 1691- 1710. doi: 10.1021/acs.jmedchem.5b01091
18. Benetti E, Mastrocola R, Vitarelli G, et al. Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation. J Pharmacol Exp Ther. 2016; 359(1): 45-53. doi: 10.1124/jpet.116.235069
19. Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol. 2011; 22(6): 1007-1018. doi: 10.1681/ASN.2010080798
20. Chen K, Zhang J, Zhang W, et al. ATP-P2X4 signaling mediates NLRP3 inflammasome activation: A novel pathway of diabetic nephropathy. Int J Biochem Cell Biol. 2013; 45(5): 932-943. doi: 10.1016/j.biocel.2013.02.009
21. Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016; 12(1): 13-26. doi: 10.1038/nrneph.2015.175